Intervention of Suxiao Jiuxin Pill on Instability of Vulnerable Plaque in Acute Myocardial Infarction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Suxiao Jiuxin Pills, The placebo of Suxiao Jiuxin Pills.
- Who it may be relevant to
- Registry conditions: Acute Myocardial Infarction. Basic parameters: 30 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Clinical Trial of Suxiao Jiuxin Pill on the Instability of Vulnerable Plaque With Integrated Traditional Chinese Medicine and Western Medicine in Acute ST-segment Elevation Myocardial Infarction(STEMI) Patient
Overview
The incidence of cardiovascular disease is still high in China under the condition of non-standard treatment of Western medicine. Acute coronary plaque rupture and thrombosis is an extreme manifestation of instability of "vulnerable plaque", which is the result of the joint action of multiple factors. The intervention of unstable plaque reversal from multiple factors is inherently reasonable. Compared with the treatment of thrombosis and unstable plaque in western medicine, quick acting Jiuxin Pill can not only calm and relieve pain for pain and other symptoms, but also regulate immune inflammation and metabolic disorder, improve microcirculation and anti myocardial ischemia. In order to evaluate the efficacy, safety and modern scientific basis of Suxiao Jiuxin Pill in acute myocardial infarction (AMI), the investigators designed this study.
Detailed description
Under the condition of standardized western medicine treatment, the incidence and disability rate of cardiovascular disease in China is still high. There has been a wealth of clinical practice in the treatment of acute myocardial infarction with traditional Chinese medicine, and clinical evidence-based exploration is an inevitable trend. Suxiao Jiuxin Pill is a classic old medicine, but large-scale randomized controlled trial are still needed to consolidate the efficacy, safety and modern scientific basis in acute myocardial infarction (AMI). This pilot single center standardization research is the most basic support and exploration. This project can enhance the influence of Suxiao Jiuxin pills in the context of modern science, which will help the products to be more widely used in Chinese and western hospitals, benefit more patients, reduce the health economics cost of patients with acute ischemia of coronary heart disease at home and abroad, and reduce the social burden. From the perspective of local "vulnerable plaque" instability and "vulnerable patients" systemic inflammation outbreak driving plaque rupture, this study aims to clarify the effect of Suxiao Jiuxin Pill on thrombotic lesions, systemic and clinical short-term prognosis in patients with acute ST segment elevation myocardial infarction (STEMI) from multi-target and multi-component. This study provides evidence for the mechanism of Suxiao Jiuxin Pill in the comprehensive prevention and treatment of pathophysiological disorders in STEMI patients.
Interventions
- Drug Suxiao Jiuxin Pills
Suxiao Jiuxin Pills consists Rhizoma Ligustici (Chuan xiong) and Borneolum (Bing pian). - Drug The placebo of Suxiao Jiuxin Pills
The placebo of Suxiao Jiuxin Pills is similar to Suxiao Jiuxin Pills in appearance, smell, and taste.
Primary outcome measures
- Changes of MMP-9 [Time frame: Up to 30 minutes after administration]
Secondary outcome measures (11)
- Changes of TIMI myocardial perfusion (TMP) of "criminal vessel". [Time frame: Up to 30 minutes after administration]
- Changes in the local morphology of vulnerable plaque [Time frame: Up to 30 minutes after administration]
- Changes of PCSK9 in vulnerable plaque [Time frame: Up to 30 minutes after administration]
- Expression changes of local SMC-FC transformation indexes in vulnerable plaque [Time frame: Up to 30 minutes after administration]
- Expression changes of Local EC function index of vulnerable plaque [Time frame: Up to 30 minutes after administration]
- Expression changes of Local angiogenic factors in vulnerable plaque [Time frame: Up to 30 minutes after administration]
- Expression changes of indicators associated with vulnerable plaque rupture events [Time frame: Up to 30 minutes after administration]
- Changes in coagulation related indicators in vulnerable plaque [Time frame: Up to 30 minutes after administration]
- The changes of inflammation related indicators [Time frame: 3 months after PCI]
- Changes of remodeling indexes [Time frame: 3 months after PCI]
- Changes in the incidence of MACE [Time frame: 3 months after PCI]
Eligibility criteria
Inclusion criteria
- Between the ages of 18-75;
- Meet the diagnosis of AMI global definition version 4，admit from emergency department;
- Prepare for emergency coronary angiography and PCI reperfusion therapy;
- Volunteer to participate in this study and have signed an informed consent form.
Exclusion criteria
- AMI with cardiogenic shock (Killip grade ≥ grade III) and no response to vasopressin;
- AMI complicated with severe arrhythmia (persistent ventricular tachycardia, ventricular fibrillation);
- AMI complicated with mechanical complications (ventricular septal perforation, papillary muscle rupture, intracardiac thrombus, ventricular free wall rupture);
- Severe systemic diseases (immune system diseases, sepsis and other serious infections, blood system diseases, massive hemorrhage caused by anticoagulation and antithrombotic therapy, and severe organ failure (such as ALT ≥ 3 ULN, cr> 134 μ Mol/l (2mg/dl) or egfr<45ml/min/1.73m2);
- History of cerebral hemorrhage and cerebral aneurysm within 3 months;
- Mental patients;
- Malignant tumor or other pathophysiological condition with expected survival less than 1 year;
- Those who are allergic to the drug components of this study;
- Pregnant or lactating women;
- Patients who have participated in clinical trials of other drugs within 3 months before enrollment or took other Chinese patent medicines with similar effects within the first three months of enrollment;
- Other diseases with clinical significance that may cause serious danger to patients.
- In TCM syndrome types, Qi deficiency, Yang deficiency and other deficiency syndrome types, and cold congealing heart pulse syndrome types in positive syndrome types.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
China · 1 center
- Xiaolu Li — Jinan
Identifiers
NCT: NCT05466968 · YXLL-KY-2022(030)